Markets & Finance

Citigroup Ups Pain Therapeutics to Hold

Citigroup upgraded Pain Therapeutics (PTIE) to hold from sell, after news that the drug maker's painkiller Oxytrex failed to in a trial.

While citing these "clouded results," analyst Andrew Swanson says that management has affirmed its plan to continue developing the drug, with a new trial expected to begin in 2006. He says he's always assumed a third trial would be required for approval of the drug; as such, he keeps his forecasts on the company's earnings, which assume a second quarter 2008 launch for Oxytrex.

Steve Ballmer, Power Forward

Sponsored Financial Commentaries

Sponsored Links

Buy a link now!

blog comments powered by Disqus